<DOC>
	<DOC>NCT01786096</DOC>
	<brief_summary>This is a phase 1, open-label, dose-escalation, multicenter study to evaluate the safety and tolerability of SGN-CD19A in adult and pediatric patients with relapsed or refractory B-lineage acute lymphoblastic leukemia (B-ALL), Burkitt lymphoma or leukemia, or B-lineage lymphoblastic lymphoma (B-LBL).</brief_summary>
	<brief_title>A Safety Study of SGN-CD19A for Leukemia and Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia, Lymphoid</mesh_term>
	<mesh_term>Burkitt Lymphoma</mesh_term>
	<mesh_term>Precursor B-Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<criteria>Adult patients must be relapsed or refractory to at least 1 prior multiagent systemic therapy. Pediatric patients must be relapsed or refractory to at least 2 prior multiagent systemic therapies. Patients with acute lymphoblastic leukemia who are Philadelphia chromosomepositive must have failed a second generation tyrosine kinase inhibitor. Eastern Cooperative Oncology Group status of 2 or lower Pathologically confirmed diagnosis of Blineage acute lymphoblastic leukemia, Burkitt leukemia or lymphoma, or Blineage lymphoblastic lymphoma Measurable disease Allogeneic stem cell transplant within 60 days, active acute or chronic graftversushost disease (GvHD), or receiving immunosuppressive therapy as treatment for GvHD</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Burkitt Lymphoma</keyword>
	<keyword>Antibodies, Monoclonal</keyword>
	<keyword>Antibody-Drug Conjugate</keyword>
	<keyword>B-Lineage Acute Lymphoblastic Leukemia</keyword>
	<keyword>B-Lineage Lymphoblastic Lymphoma</keyword>
	<keyword>Burkitt Leukemia</keyword>
	<keyword>Monomethylauristatin F</keyword>
	<keyword>Antigens, CD19</keyword>
	<keyword>Drug Therapy</keyword>
</DOC>